NEW YORK (AP) _ Progenics Pharmaceuticals Inc. (PGNX) on Thursday reported a loss of $14.7 million in its fourth quarter.
On a per-share basis, the New York-based company said it had a loss of 17 cents.
The biopharmaceutical company posted revenue of $3.2 million in the period.
For the year, the company reported that its loss widened to $67.7 million, or 87 cents per share. Revenue was reported as $15.6 million.
The company's shares closed at $4.21. A year ago, they were trading at $8.28.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PGNX at https://www.zacks.com/ap/PGNX